Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on June 22, 2026, covering events occurring on June 22, 2026, and June 25, 2026. The company operates in the pharmaceutical sector, focusing on intestinal failure programs and the development of crofelemer for microvillus inclusion disease (MVID).
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on material agreements and corporate actions rather than periodic financial results.
Material Changes and Corporate Actions
- Manufacturing Agreement Amendment: On June 22, 2026, the Company and its subsidiary Napo Pharmaceuticals, Inc. entered into a First Amendment to a Manufacturing and Supply Agreement with Woodward Specialty LLC. This amendment clarifies inventory title transfer, establishes that Napo will manage inventory until the earlier of specific conditions being met or December 31, 2026, and assigns certain costs and liabilities to Woodward to ensure business continuity during operational transitions.
- Stock Conversion: On June 25, 2026, the Company announced the conversion of all outstanding Series O Convertible Preferred Stock into shares of Common Stock. Each share of Preferred Stock converts into 3.209 shares of Common Stock, effective at 12:00 pm Eastern Time on June 25, 2026.
Guidance, Outlook, and Risks
Management provided forward-looking statements regarding the following:
- Clinical Milestones: Expectation that the intestinal failure program will continue to provide clinical proof-of-concept milestones.
- Funding Strategy: Anticipation of potential non-dilutive funding from licensee partners to support the intestinal failure program.
- Regulatory Path: Plans to pursue Breakthrough Therapy designation for crofelemer for MVID and an expectation to file a New Drug Application (NDA) with the FDA for the MVID indication in the first half of 2027.
- Risks: The filing includes standard disclaimers that actual results may differ materially from expectations due to various risk factors detailed in the Company's 2025 Form 10-K.
Investor Verification Checklist
- Verify the exact number of Series O Preferred Shares converted and the resulting increase in Common Stock shares outstanding.
- Review the full text of the First Amendment to Manufacturing and Supply Agreement (Exhibit 10.1) to understand specific cost allocations and liability shifts with Woodward Specialty LLC.
- Monitor the timeline for the anticipated NDA filing for MVID in the first half of 2027.
- Check for subsequent press releases or filings regarding the status of the inventory transition and licensing discussions for the intestinal failure program.